535 results on '"Leblond, Véronique"'
Search Results
2. Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study
3. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
4. Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
5. A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
6. Cerebral vasculitis due to Aspergillus spp. in immunocompromised patients: literature review
7. Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments
8. Distinct immunopathological mechanisms of EBV-positive and EBV-negative posttransplant lymphoproliferative disorders
9. Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia
10. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
11. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial
12. CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell–targeted therapies
13. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
14. Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features
15. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53
16. Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study
17. The Mutator Pathway Is a Feature of Immunodeficiency-Related Lymphomas
18. P1679: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) TREATED WITH ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR): RESULTS FROM THE PHASE 3 ASPEN TRIAL LONG-TERM FOLLOW-UP
19. P650: EFFECTIVENESS OF VENETOCLAX ACCORDING TO THE CHARACTERISTICS OF PATIENTS WITH CLL IN MONOTHERAPY AND COMBINATION WITH RITUXIMAB. INTERIM ANALYSIS OF REAL-LIFE DATA FROM VERONE STUDY
20. Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management
21. Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
22. Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia
23. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia
24. TCL1 expression patterns in Waldenström macroglobulinemia
25. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL
26. Successful Voriconazole Treatment of Disseminated Fusarium Infection in an Immunocompromised Patient
27. Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)
28. Real-World Efficacy and Safety of Venetoclax Alone and in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia: Interim Results of the Verone Study
29. EBV Dictates Lower Tumor Neoepitopes Scores and Intra-Tumoral Repertoire Diversity in NHL from Immuno-Compromized Patients
30. A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial
31. Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
32. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study
33. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
34. Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)
35. Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC‐based first‐line treatment: Retrospective observations from the FILO group
36. Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstromʼs macroglobulinemia
37. Supplementary files of the article Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström’s Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study [Dataset]
38. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström’s Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
39. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial
40. TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia
41. Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia
42. A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia
43. Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC
44. Mast cell density and its clinical relevance in Waldenström's macroglobulinemia
45. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia
46. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
47. Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients
48. Lenalidomide is safe and active in Waldenström macroglobulinemia
49. A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial
50. Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.